Targeting butyrylcholinesterase for preclinical single photon emission computed tomography (SPECT) imaging of Alzheimer's disease

Alzheimer's and Dementia: Translational Research and Clinical Interventions - Tập 3 - Trang 166-176 - 2017
Drew R. DeBay1,2, George A. Reid1, Ian R. Pottie3,4, Earl Martin3, Chris V. Bowen2,5, Sultan Darvesh1,2,3,6
1Department of Medical Neuroscience, Dalhousie University, Halifax, Nova Scotia, Canada
2Biomedical Translational Imaging Centre, Halifax, Nova Scotia, Canada
3Department of Chemistry and Physics, Mount Saint Vincent University, Halifax, Nova Scotia, Canada
4Department of Chemistry Saint Mary’s, University Halifax, Nova Scotia, Canada
5Department of Radiology; Dalhousie University; Halifax, Nova Scotia, Canada.
6Department of Medicine, Dalhousie University, Halifax, Nova Scotia Canada

Tóm tắt

AbstractIntroductionDiagnosis of Alzheimer's disease (AD) in vivo, by molecular imaging of amyloid or tau, is constrained because similar changes can be found in brains of cognitively normal individuals. Butyrylcholinesterase (BChE), which becomes associated with these structures in AD, could elevate the accuracy of AD diagnosis by focusing on BChE pathology in the cerebral cortex, a region of scant BChE activity in healthy brain.MethodsN‐methylpiperidin‐4‐yl 4‐[123I]iodobenzoate, a BChE radiotracer, was injected intravenously into B6SJL‐Tg(APPSwFlLon, PSEN1∗M146 L∗L286 V) 6799Vas/Mmjax (5XFAD) mice and their wild‐type (WT) counterparts for comparative single photon emission computed tomography (SPECT) studies. SPECT, computed tomography (CT), and magnetic resonance imaging (MRI) enabled comparison of whole brain and regional retention of the BChE radiotracer in both mouse strains.ResultsRetention of the BChE radiotracer was consistently higher in the 5XFAD mouse than in WT, and differences were particularly evident in the cerebral cortex.DiscussionCerebral cortical BChE imaging with SPECT can distinguish 5XFAD mouse model from the WT counterpart.

Tài liệu tham khảo

10.1016/S0140-6736(15)01124-1 10.1097/00005072-199710000-00002 10.1016/j.jalz.2011.03.005 10.3233/JAD-2011-110458 10.1002/ana.20009 10.1016/j.nucmedbio.2005.06.001 10.1021/jm050166g 10.1021/jm8013376 10.1016/S1474-4422(14)70252-2 10.2967/jnumed.113.120618 10.1177/070674370404900303 10.1016/S1474-4422(12)70142-4 10.1016/j.jalz.2015.02.004 10.1001/jamaneurol.2014.4144 10.1001/jamaneurol.2016.2078 10.1016/S0074-7742(09)00407-3 10.2967/jnumed.115.163717 10.1016/j.jalz.2016.02.002 10.1016/S0140-6736(76)91936-X 10.1126/science.7046051 10.1126/science.6338589 10.1111/j.1365-2990.1978.tb00545.x 10.1002/ana.410360506 10.2174/1567205013666160404120542 10.1007/BF02984999 10.1002/ana.20672 Irie T., 1996, Brain acetylcholinesterase activity: Validation of a PET tracer in a rat model of Alzheimer's disease, J Nucl Med, 37, 649 10.1046/j.1471-4159.1996.67020876.x 10.1016/S0969-8051(98)00045-6 10.1016/S1046-2023(02)00081-6 10.1016/j.bmcl.2004.01.080 10.1097/00004647-200102000-00004 10.1097/WNF.0b013e3181c71be9 Roivainen A., 2004, Biodistribution and blood metabolism of 1‐11C‐methyl‐4‐piperidinyl n‐butyrate in humans: an imaging agent for in vivo assessment of butyrylcholinesterase activity with PET, J Nucl Med, 45, 2032 10.1097/00002093-199501002-00005 10.1016/0006-8993(94)91697-7 10.1002/ana.410420613 10.2174/156720510791383868 10.2967/jnumed.115.162032 10.1007/s11307-010-0448-0 10.1523/JNEUROSCI.1202-06.2006 10.1016/j.cbi.2016.04.022 10.1016/j.neuroscience.2015.04.039 10.1016/0742-8413(86)90152-0 10.2174/1567205011666140505111354 10.1162/153535003322556877 10.1016/j.neuroscience.2005.07.014 10.1097/00004728-199801000-00027 Perry E., 2003, Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies, Neurology, 60, 1852, 10.1212/01.WNL.0000068336.84399.9E 10.1007/s10571-011-9770-6
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Translational Research and Clinical Interventions

Tập 3

166-176

Thông tin tác giả